Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1 -- 2108 2024-03-13 11:37:23 |
2 layout & references Meta information modification 2108 2024-03-15 09:08:17 |

Video Upload Options

Do you have a full video?

Confirm

Are you sure to Delete?
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Giuliani, S.; Paraboschi, I.; Mcnair, A.; Smith, M.; Rankin, K.S.; Elson, D.S.; Paleri, V.; Leff, D.; Stasiuk, G.; Anderson, J. Monoclonal Antibodies for Targeted Fluorescence-Guided Surgery. Encyclopedia. Available online: https://encyclopedia.pub/entry/56204 (accessed on 16 April 2024).
Giuliani S, Paraboschi I, Mcnair A, Smith M, Rankin KS, Elson DS, et al. Monoclonal Antibodies for Targeted Fluorescence-Guided Surgery. Encyclopedia. Available at: https://encyclopedia.pub/entry/56204. Accessed April 16, 2024.
Giuliani, Stefano, Irene Paraboschi, Angus Mcnair, Myles Smith, Kenneth S. Rankin, Daniel S. Elson, Vinidh Paleri, Daniel Leff, Graeme Stasiuk, John Anderson. "Monoclonal Antibodies for Targeted Fluorescence-Guided Surgery" Encyclopedia, https://encyclopedia.pub/entry/56204 (accessed April 16, 2024).
Giuliani, S., Paraboschi, I., Mcnair, A., Smith, M., Rankin, K.S., Elson, D.S., Paleri, V., Leff, D., Stasiuk, G., & Anderson, J. (2024, March 13). Monoclonal Antibodies for Targeted Fluorescence-Guided Surgery. In Encyclopedia. https://encyclopedia.pub/entry/56204
Giuliani, Stefano, et al. "Monoclonal Antibodies for Targeted Fluorescence-Guided Surgery." Encyclopedia. Web. 13 March, 2024.
Monoclonal Antibodies for Targeted Fluorescence-Guided Surgery
Edit

Due to their specificity, monoclonal antibodies have significantly impacted cancer patients’ care, becoming one of the fastest-growing classes of new drugs approved for the treatment of solid tumors. Targeted fluorescence-guided surgery is a novel technology to better visualize tumor residuals intraoperatively. It consists of a fluorescent molecular probe, that, once injected, lights up the neoplastic cells during the surgical resection. In this regard, the development of an off-the-shelf large-scale production of clinically approved, fluorescently labeled monoclonal antibodies for targeted fluorescence-guided surgery is becoming an urgent need for oncological surgeons working in this field.

monoclonal antibodies targeted fluorescence-guided surgery solid malignancies surgical oncology fluorophores

1. Introduction

Due to their target specificity and immunomodulatory properties, monoclonal antibodies (mAbs) have significantly impacted cancer patients’ care, becoming one of the fastest growing groups of new drugs approved for the cure of solid tumors [1]. mAbs have been effectively used to elicit long-lasting effector responses against solid malignancies by exploiting their unique capability of directly killing cancer cells while simultaneously activating the host immune system [1]. As a form of radioimmunotherapy, mAbs have also been adopted to selectively deliver high doses of radiation to tumor cells while also reducing the exposure of the surrounding healthy tissues, thus enhancing the efficacy of standard radiotherapy while minimizing its side effects [2].
Recently, fluorescently labeled mAbs have been used in the operating theatre to help surgeons better visualize and remove solid tumors in real time. This has been a revolution in the field of targeted fluorescence-guided surgery (T-FGS). Even if the adoption of fluorescently labeled mAbs in surgical oncology is still in its infancy, its applications are growing fast, with real potential to revolutionize the surgical field [3][4][5][6][7][8][9][10]. In this regard, the development of an “off-the-shelf” large-scale production of clinically approved fluorescently labeled mAbs is becoming an urgent need for oncological surgeons working in this surgical field.

2. Fluorescence-Guided Surgery (FGS): Non-Specific and Monoclonal Antibody (mAb)-Targeted

FGS is an emerging imaging tool that permits surgeons to identify healthy and pathological tissues, in real time, by intravenously delivering non-specific fluorophores (e.g., indocyanine green (ICG), 5-aminolevulinic acid, or fluorescein sodium) or fluorescently labeled molecules with a particular tissue or tumor tropism (e.g., mAbs). Depending on their route of administration, systemically administered non-specific fluorescent dyes can be used to help surgeons identify blood, bile, and lymphatic vessels during surgery, bridging the gap existing between preoperative anatomical imaging and patient-specific surgical findings [11][12].
In the surgical oncology field, non-specific dyes could be employed to distinguish neoplastic lesions from the surrounding normal tissues, by exploiting the enhanced permeability and retention (EPR) effects caused by the leaky nature of tumor vessels and the compromised lymphatic drainage [3][4][5][6][7][8][9]. Unfortunately, non-specific dyes are often unable to cause tumors from a diverse range of cancer types to fluoresce effectively as the EPR effect is not homogenous or reliable.
Besides non-specific fluorescent dyes, fluorophores have been conjugated to mAbs to deliver T-FGS, thus enhancing the intraoperative visualization of cancer at the tumor margins, loco-regional lymph nodes, and occult disease with high resolution and deep tissue penetration. By binding to a specific site of the tumor antigen (i.e., epitope), fluorescently labeled mAbs can be administered a few days before surgery, and then visualized using new-generation near-infrared (NIR) camera systems for endoscopic and open-field procedures [3][4][5][6][7][8][9].
Building on the widespread use of non-specific FGS and ICG, biomedical device companies have developed several NIR fluorescence platforms, which can be used to detect mAb-based FGS [3][4][5][8]. Briefly, the fluorophore-conjugated mAb needs to be excited at a specific wavelength to produce an invisible light, which will be collected at a set wavelength range to be transformed into an image. For surgical indications, mAbs have been conjugated to NIR dyes (e.g., IRDye800CW; wavelengths: 650–900 nm), which provide low absorption in healthy tissue, high tumor-to-background-ratio (TBR) and tissue penetration, with low interference from intrinsic fluorescence, especially when compared to the visible light spectrum (wavelengths: 400–600 nm). By doing so, the non-specific tissue background can be minimized while the tumor cells can be illuminated in real-time helping surgeons with better visualization [3][4][5][6][7][8][9].

3. Monoclonal Antibodies (mAbs) Clinically Approved for the Treatment of Extra-Hematological Solid Malignancies under Evaluation in Clinical Trials for T-FGS Purposes

In this section, mAbs clinically approved for the treatment of extra-hematological solid malignancies are summarized in Table 1 and Table 2.
Table 1. Monoclonal antibodies (mAbs) clinically approved for the treatment of solid extra-hematological malignancies.
Table 2. Monoclonal antibodies (mAbs) conjugated to the near-infrared I (NIR-I) fluorescent dye IRDye800CW for the intraoperative imaging of solid extra-hematological malignancies.

References

  1. Zahavi, D.; Weiner, L. Monoclonal Antibodies in Cancer Therapy. Antibodies 2020, 9, 34.
  2. Larson, S.M.; Carrasquillo, J.A.; Cheung, N.-K.V.; Press, O.W. Radioimmunotherapy of human tumours. Nat. Rev. Cancer 2015, 15, 347–360.
  3. Nagaya, T.; Nakamura, Y.A.; Choyke, P.L.; Kobayashi, H. Fluorescence-Guided Surgery. Front. Oncol. 2017, 7, 314.
  4. Nguyen, Q.T.; Tsien, R.Y. Fluorescence-guided surgery with live molecular navigation—A new cutting edge. Nat. Rev. Cancer 2013, 13, 653–662.
  5. Paraboschi, I.; De Coppi, P.; Stoyanov, D.; Anderson, J.; Giuliani, S. Fluorescence imaging in pediatric surgery: State-of-the-art and future perspectives. J. Pediatr. Surg. 2021, 56, 655–662.
  6. Privitera, L.; Paraboschi, I.; Dixit, D.; Arthurs, O.J.; Giuliani, S. Image-guided surgery and novel intraoperative devices for enhanced visualisation in general and paediatric surgery: A review. Innov. Surg. Sci. 2022, 6, 161–172.
  7. Tipirneni, K.E.; Warram, J.M.; Moore, L.S.; Prince, A.C.; de Boer, E.; Jani, A.H.; Wapnir, I.L.; Liao, J.C.; Bouvet, M.; Behnke, N.K.; et al. Oncologic Procedures Amenable to Fluorescence-guided Surgery. Ann. Surg. 2017, 266, 36–47.
  8. Vahrmeijer, A.L.; Hutteman, M.; van der Vorst, J.R.; van de Velde, C.J.H.; Frangioni, J.V. Image-guided cancer surgery using near-infrared fluorescence. Nat. Rev. Clin. Oncol. 2013, 10, 507–518.
  9. Choi, N.; Jeong, H.-S. Precision surgery for cancer: A new surgical concept in individual tumor biology-based image-guided surgery. Precis. Future Med. 2019, 3, 116–123.
  10. Wang, K.; Du, Y.; Zhang, Z.; He, K.; Cheng, Z.; Yin, L.; Dong, D.; Li, C.; Li, W.; Hu, Z.; et al. Fluorescence image-guided tumour surgery. Nat. Rev. Bioeng. 2023, 1, 161–179.
  11. Preziosi, A.; Paraboschi, I.; Giuliani, S. Evaluating the Development Status of Fluorescence-Guided Surgery (FGS) in Pediatric Surgery Using the Idea, Development, Exploration, Assessment, and Long-Term Study (IDEAL) Framework. Children 2023, 10, 689.
  12. Ishizawa, T.; McCulloch, P.; Stassen, L.; Van Den Bos, J.; Regimbeau, J.-M.; Dembinski, J.; Schneider-Koriath, S.; Boni, L.; Aoki, T.; Nishino, H.; et al. Assessing the development status of intraoperative fluorescence imaging for anatomy visualisation, using the IDEAL framework. BMJ Surg. Interv. Health Technol. 2022, 4, e000156.
  13. Herbst, R.S.; Shin, D.M. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: A new paradigm for cancer therapy. Cancer 2002, 94, 1593–1611.
  14. Martinelli, E.; De Palma, R.; Orditura, M.; De Vita, F.; Ciardiello, F. Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin. Exp. Immunol. 2009, 158, 1–9.
  15. Holmes, K.; Roberts, O.L.; Thomas, A.M.; Cross, M.J. Vascular endothelial growth factor receptor-2: Structure, function, intracellular signalling and therapeutic inhibition. Cell. Signal. 2007, 19, 2003–2012.
  16. Hsu, J.Y.; Wakelee, H.A. Monoclonal Antibodies Targeting Vascular Endothelial Growth Factor: Current Status and Future Challenges in Cancer Therapy. BioDrugs 2009, 23, 289–304.
  17. Chen, K.-T.; Seimbille, Y. New Developments in Carbonic Anhydrase IX-Targeted Fluorescence and Nuclear Imaging Agents. Int. J. Mol. Sci. 2022, 23, 6125.
  18. Forker, L.; Gaunt, P.; Sioletic, S.; Shenjere, P.; Potter, R.; Roberts, D.; Irlam, J.; Valentine, H.; Hughes, D.; Hughes, A.; et al. The hypoxia marker CAIX is prognostic in the UK phase III VorteX-Biobank cohort: An important resource for translational research in soft tissue sarcoma. Br. J. Cancer 2018, 118, 698–704.
  19. Lai, Y.; Zeng, T.; Liang, X.; Wu, W.; Zhong, F.; Wu, W. Cell death-related molecules and biomarkers for renal cell carcinoma targeted therapy. Cancer Cell Int. 2019, 19, 221.
  20. De Gooyer, J.M.; Elekonawo, F.M.K.; Bremers, A.J.A.; Boerman, O.C.; Aarntzen, E.H.J.G.; De Reuver, P.R.; Nagtegaal, I.D.; Rijpkema, M.; De Wilt, J.H.W. Multimodal CEA-targeted fluorescence and radioguided cytoreductive surgery for peritoneal metastases of colorectal origin. Nat. Commun. 2022, 13, 2621.
More
Information
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register : , , , , , , , , ,
View Times: 52
Revisions: 2 times (View History)
Update Date: 15 Mar 2024
1000/1000